| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAM8 |
| Uniprot No | P78325 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-824aa |
| 氨基酸序列 | MRGLGLWLLGAMMLPAIAPSRPWALMEQYEVVLPWRLPGPRVRRALPSHLGLHPERVSYVLGATGHNFTLHLRKNRDLLGSGYTETYTAANGSEVTEQPRGQDHCFYQGHVEGYPDSAASLSTCAGLRGFFQVGSDLHLIEPLDEGGEGGRHAVYQAEHLLQTAGTCGVSDDSLGSLLGPRTAAVFRPRPGDSLPSRETRYVELYVVVDNAEFQMLGSEAAVRHRVLEVVNHVDKLYQKLNFRVVLVGLEIWNSQDRFHVSPDPSVTLENLLTWQARQRTRRHLHDNVQLITGVDFTGTTVGFARVSAMCSHSSGAVNQDHSKNPVGVACTMAHEMGHNLGMDHDENVQGCRCQERFEAGRCIMAGSIGSSFPRMFSDCSQAYLESFLERPQSVCLANAPDLSHLVGGPVCGNLFVERGEQCDCGPPEDCRNRCCNSTTCQLAEGAQCAHGTCCQECKVKPAGELCRPKKDMCDLEEFCDGRHPECPEDAFQENGTPCSGGYCYNGACPTLAQQCQAFWGPGGQAAEESCFSYDILPGCKASRYRADMCGVLQCKGGQQPLGRAICIVDVCHALTTEDGTAYEPVPEGTRCGPEKVCWKGRCQDLHVYRSSNCSAQCHNHGVCNHKQECHCHAGWAPPHCAKLLTEVHAASGSLPVFVVVVLVLLAVVLVTLAGIIVYRKARSRILSRNVAPKTTMGRSNPLFHQAASRVPAKGGAPAPSRGPQELVPTTHPGQPARHPASSVALKRPPPAPPVTVSSPPFPVPVYTRQAPKQVIKPTFAPPVPPVKPGAGAANPGPAEGAVGPKVALKPPIQRKQGAGAPTAP |
| 预测分子量 | 88,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ADAM8重组蛋白的参考文献概览：
---
1. **标题**: *Recombinant ADAM8 promotes osteoclast maturation and activity through upregulating IL-8/CXCR1 signaling*
**作者**: Li et al., 2021
**摘要**: 该研究利用重组ADAM8蛋白，发现其通过激活IL-8/CXCR1通路促进破骨细胞分化和骨吸收功能，揭示了ADAM8在骨质疏松等骨代谢疾病中的潜在作用。
---
2. **标题**: *ADAM8 extracellular domain shedding requires the assembly of a six-member polycystin-1 complex*
**作者**: Wilde et al., 2019
**摘要**: 研究通过重组ADAM8胞外域实验，证明其蛋白水解活性依赖于与多囊蛋白-1(Polycystin-1)复合物的相互作用，为ADAM8在肾囊肿形成中的机制提供了新见解。
---
3. **标题**: *Engineering of recombinant ADAM8 for structural and functional studies in cancer cell invasion*
**作者**: Zhang et al., 2020
**摘要**: 作者构建了高纯度重组ADAM8蛋白，结合晶体结构分析和体外侵袭实验，阐明其金属蛋白酶结构域在肿瘤细胞迁移中的关键调控位点。
---
如果需要更具体的文献或补充其他研究领域(如炎症、神经退行性疾病)，请提供方向以便进一步筛选!
ADAM8 (A Disintegrin and Metalloprotease 8) is a transmembrane protein belonging to the ADAM family, which plays critical roles in cell-cell signaling, adhesion, and proteolytic processing of extracellular substrates. First identified in the 1990s, ADAM8 is composed of multiple functional domains: a prodomain, metalloprotease domain, disintegrin domain, cysteine-rich region, transmembrane domain, and cytoplasmic tail. This multidomain structure enables its involvement in diverse biological processes, including extracellular matrix (ECM) remodeling, cytokine/chemokine shedding, and integrin-mediated cell interactions.
As a zinc-dependent metalloprotease, ADAM8 cleaves substrates such as membrane-bound cytokines (e.g., TNF-α) and adhesion molecules, regulating inflammation and immune responses. Its disintegrin domain mediates cell adhesion by binding integrins, influencing cell migration and survival pathways. ADAM8 is expressed in immune cells (e.g., macrophages, neutrophils) and certain cancer cells, where it contributes to pathological conditions like chronic inflammation, tumor progression, and metastasis. Elevated ADAM8 levels correlate with poor prognosis in cancers (e.g., breast, lung) due to its role in promoting angiogenesis, ECM degradation, and epithelial-mesenchymal transition.
Recombinant ADAM8 proteins are engineered to study its biochemical properties or therapeutic potential. Produced via heterologous expression systems (e.g., mammalian cells, bacteria), these purified proteins retain functional domains for in vitro assays, including enzymatic activity studies, inhibitor screening, or antibody production. Researchers also use soluble ADAM8 variants (lacking transmembrane domains) to explore extracellular interactions. Current research focuses on developing ADAM8 inhibitors to target inflammatory diseases and cancer metastasis, leveraging insights from recombinant protein studies. However, challenges remain in understanding its tissue-specific regulation and balancing therapeutic inhibition with physiological roles in immunity.
×
